The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients

Using Circulating Tumor Cells to Diagnose and Predict Prognosis in Metastatic Nasopharyngeal Carcinoma Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02505139

Enrollment

166

Registered

2015-07-22

Start date

2014-12-31

Completion date

2016-08-31

Last updated

2016-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Neoplasms

Keywords

nasopharyngeal carcinoma, distant metastasis, circulating tumor cells, outcome prediction

Brief summary

A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma (mNPC) patients is not unknown. Through the observational prospective clinical trial, sensitivity, specificity, positive and negative predictive values of CTC in diagnosis of mNPC patients will be gained. Further, the value of CTC in outcome prediction of mNPC patients will be uncovered.

Interventions

OTHERthe number of circulating tumor cells

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Histologically or radiologically confirmed nasopharyngeal non-keratinizing carcinoma (WHO II, III). * NPC patients with distant metastasis including synchronous distant metastasis at diagnosis and metachronous distant metastasis after radical treatment. * A Karnofsky performance status score more than 70. * The participants provided written informed consent.

Exclusion criteria

* A history of previous or synchronous malignant tumors. * Suffering from severe mental illness synchronously. * Suffering from severe heart or lung diseases. * Obvious abnormality in liver and renal function. * Women in pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Overall survival rate	3 years

Secondary

Measure	Time frame	Description
The proportion of positives that are correctly identified as such	3 years	number of true positives divided by (number of true positives plus number of false negatives)
The proportion of negatives that are correctly identified as such	3 years	number of true negatives divided by (number of true negatives plus number of false positives)
The proportions of positive results in statistics and diagnostic tests that are true positive results.	3 years	number of true positives divided by number of positive calls
The proportions of negative results in statistics and diagnostic tests that are true negative results.	3 years	number of true negatives divided by number of negative calls

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026